OCA improves event free survival – EASL 2022 – POSTER

OCA improves event free survival – EASL 2022 – POSTER

Long-term obeticholic acid (OCA) for primary biliary cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL PBC real-world database

Patients treated with OCA in a trial setting demonstrated a statistically significant

and clinically meaningful 58% reduction in relative risk of hepatic decompensation, LT or death

compared to non-OCA treated patients in the GLOBAL PBC registry. Reduction in risk was

independent of cirrhosis. These results support the continued use of long-term OCA therapy to

optimize prognosis of patients with PBC. SEE POSTER.


Carla Fiorella Murillo Perez, Femi Adekunle, Tracy Mayne, Elizabeth Malecha, Erik Ness, Adriaan Van der Meer, Willem Lammers, Palak Trivedi , Pier Maria Battezzati, Frederik Nevens, Kris Kowdley, Tony Bruns, Nora Cazzagon, Annarosa Floreani, Andrew L. Mason, Albert Pares, Maria Carlota Londoño, Pietro Invernizzi, Marco Carbone, Ana Lleo, Marlyn J. Mayo, George Dalekos, Nikolaos Gatselis, Douglas Thorburn, Verhelst Xavier,  Aliya Gulamhusein, Harry LA Janssen, Michael Trauner, Christopher Bowlus, Keith D. Lindor, Christophe Corpechot, Gideon Hirschfield, Bettina Hansen